VTRS · 10-Q · 2026Q3 · Full report

Revenue Performance and Mix

Viatris Inc · 2026-11-05 · Importance 31 · Surprise 32 · From source text

Third-quarter 2026 total revenues were $3,749.5 million, down $10.4 million from $3,759.9 million a year earlier; first-nine-month revenues rose 4% to $11,023.3 million from $10,596.3 million. Nine-month constant-currency net sales increased 2%, or $221.5 million, as approximately $286.9 million of new-product sales exceeded $65.4 million of net base-business erosion. Greater China grew 14% in the quarter and 19% over nine months, with constant-currency growth of 10% and 15%, respectively, driven by e-commerce, retail and hospital channels; Developed Markets nine-month sales rose 3%, while JANZ fell 4% and Emerging Markets fell 2%. North American estradiol transdermal sales were approximately $126.0 million in the quarter and $234.1 million over nine months; Emerging Markets’ nine-month decline was driven primarily by lower ARV volumes related to supply constraints.

Key facts

• Viatris' R&D expense for the nine months ended September 30, 2026 was $728.6 million, compared with $691.2 million in the prior-year period, an increase of $37.4 million, primarily due to higher spending on selatogrel and cenerimod development. source
• Viatris' SG&A expense for the nine months ended September 30, 2026 was $3.01 billion, compared with $2.76 billion in the prior-year period, an increase of $250.7 million. source
• For the nine months ended September 30, 2026, Viatris' adjusted net earnings were $2,324.0 million and adjusted EPS was $1.99; the prior-year figures were $2,110.6 million and $1.78, respectively. source
• Viatris reported third-quarter 2026 total revenues of $3.75 billion, down $10.4 million from the prior-year quarter; net sales were $3.73 billion, down $12.8 million, and other revenues were $14.8 million versus $12.4 million. source
• Third-quarter 2026 North America net sales were approximately $923.4 million and Europe net sales were approximately $1.29 billion. source
• First-nine-months 2026 North America net sales totaled approximately $2.63 billion and Europe net sales totaled approximately $3.80 billion. source
• Viatris reported first-nine-months 2026 total revenues of $11.02 billion, up $427.0 million or 4%; net sales were $10.99 billion, up $430.6 million or 4%, and other revenues were $33.0 million versus $36.6 million. source
• Third-quarter 2026 Developed Markets benefited from new octreotide acetate sales and approximately $126.0 million of higher estradiol transdermal product sales, both in North America. source

Impact estimates